Rosetta Genomics Inks MDx Development Deal with Moffitt Cancer Center | GenomeWeb

NEW YORK (GenomeWeb) – Rosetta Genomics announced today that it will collaborate with the Moffitt Cancer Center on the development of a microRNA-based diagnostic for thyroid neoplasia.

According to Rosetta, between four and seven percent of the general population develops thyroid nodules, but fewer than 10 percent of these are malignant. Fine needle aspiration (FNA) is routinely conducted to obtain tissue for biopsy, but analyses of these samples are often inconclusive.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.